EXECUTIVE ENGAGEMENTS
POOL
8177
Number of executives repeatedly engaged by snail & email outreach
INTERACTIONS
1143
Interactions with Platform & by Email
PARTICIPANTS
243
Unique # Participated
VALIDATIONS
86
Responses Validated*
COMPANIES
53
Responses Validated*
* Login for a full stack data experience
DATE
JUL 2022
TABLES
102
PAGES
340
EDITION
20
PRICE
USD 5450
CODE
MCP-1229
*Engagement stats are ongoing and dynamic
RESEARCH MODULES
EXECUTIVES
Global Osteoporosis Therapeutics Market to Reach $14.2 Billion by 2026
Osteoporosis constitutes a bone disorder characterized by a decreased level of bone mineral density (BMD), and/or reduced bone strength, and deterioration of bone architecture, resulting in increased risk of fractures. Afflicting more than 200 million people worldwide, the potentially life-threatening disease - osteoporosis poses a major clinical challenge to the medical world. Osteoporosis therapeutics are mainly targeted at reducing the risk of fractures, and are categorized into two main drug categories, named antiresorptive or anabolic. Antiresorptive drugs reduce bone resorption and include mainly bisphosphonates, estrogens, estrogen agonist/ antagonists [EAAs], calcitonin, and denosumab. Anabolic drugs work by increasing bone formation and include teriparatide. The osteoporosis drugs are approved by the FDA for treating Post-Menopausal Osteoporosis (PMO); Osteoporosis in men, and also GIO.
The osteoporosis therapeutics market is still largely untapped, with only about a third of osteoporosis patients being diagnosed and treated for the condition, which opens up lucrative growth opportunities for pharmaceutical companies. Factors such as aging population, growing awareness of osteoporosis, continuing new product introductions, and expansion of bone densitometry scanning, are expected to steer growth in the market. Amid the COVID-19 crisis, the global market for Osteoporosis Therapeutics estimated at US$12.7 Billion in the year 2022, is projected to reach a revised size of US$14.2 Billion by 2026, registering a compounded annual growth rate (CAGR) of 2.9% over the analysis period. United States represents the largest regional market for Osteoporosis Therapeutics, accounting for an estimated 40.8% share of the global total. The market is projected to reach US$5.5 Billion by 2026. China is expected to spearhead growth and emerge as the fastest growing regional market with a CAGR of 5.4% over the analysis period.
HIGHLIGHTS & REPORT INDEX
What`s New for 2022?
» Global competitiveness and key competitor percentage market shares
» Market presence across multiple geographies - Strong/Active/Niche/Trivial
» Online interactive peer-to-peer collaborative bespoke updates
» Access to our digital archives and MarketGlass Research Platform
» Complimentary updates for one year
Global Osteoporosis Therapeutics Market to Reach $14.2 Billion by 2026
Osteoporosis constitutes a bone disorder characterized by a decreased level of bone mineral density (BMD), and/or reduced bone strength, and deterioration of bone architecture, resulting in increased risk of fractures. Afflicting more than 200 million people worldwide, the potentially life-threatening disease - osteoporosis poses a major clinical challenge to the medical world. Osteoporosis therapeutics are mainly targeted at reducing the risk of fractures, and are categorized into two main drug categories, named antiresorptive or anabolic. Antiresorptive drugs reduce bone resorption and include mainly bisphosphonates, estrogens, estrogen agonist/ antagonists [EAAs], calcitonin, and denosumab. Anabolic drugs work by increasing bone formation and include teriparatide. The osteoporosis drugs are approved by the FDA for treating Post-Menopausal Osteoporosis (PMO); Osteoporosis in men, and also GIO.
The osteoporosis therapeutics market is still largely untapped, with only about a third of osteoporosis patients being diagnosed and treated for the condition, which opens up lucrative growth opportunities for pharmaceutical companies. Factors such as aging population, growing awareness of osteoporosis, continuing new product introductions, and expansion of bone densitometry scanning, are expected to steer growth in the market. Amid the COVID-19 crisis, the global market for Osteoporosis Therapeutics estimated at US$12.7 Billion in the year 2022, is projected to reach a revised size of US$14.2 Billion by 2026, registering a compounded annual growth rate (CAGR) of 2.9% over the analysis period. United States represents the largest regional market for Osteoporosis Therapeutics, accounting for an estimated 40.8% share of the global total. The market is projected to reach US$5.5 Billion by 2026. China is expected to spearhead growth and emerge as the fastest growing regional market with a CAGR of 5.4% over the analysis period.
The US and the Europe are the major markets for Osteoporosis therapeutics. The key factors driving the US and European osteoporosis drugs markets are the existence of well-established healthcare & medical infrastructure, favorable R&D policies towards osteoporosis drug applications, and significant investments in healthcare activities. On the other hand, developing economies are witnessing significant government and private investments in healthcare infrastructure development, driving the market for therapeutic medicines. Healthcare spending in Asia-Pacific is forecast to register a notable expansion fueled by rising consumer income, public healthcare systems` initiatives and lifestyle changes. Despite the availability of a wide variety of treatment options, inadequate awareness of osteoporosis and lack of proper diagnosis equipment have been the major factors plaguing industry growth over the years.
SELECT PLAYERS
Alergan Plc.; Amgen, Inc.; Chugai pharmaceutical; Daiichi Sankyo Co., Ltd.; Egalet Corporation; Eisai Co., Ltd.; Eli Lilly and Company; F. Hoffmann-La Roche Ltd.;
SEGMENTS
» Drug Class (Bisphosphonates, Parathyroid Hormone Therapy, Calcitonin, Selective Estrogen Inhibitors Modulator (SERM), and Rank Ligand Inhibitors) » Route of Administration (Oral, Injectables, and Other Routes of Administration)
GEOGRAPHIES
» World » United States » Canada » Japan » China » Europe » France » Germany » Italy » United Kingdom » Spain » Russia » and Rest of Europe » Asia-Pacific » Australia » India » South Korea » and Rest of Asia-Pacific » Latin America » Argentina » Brazil » Mexico » and Rest of Latin America » Middle East » Iran » Israel » Saudi Arabia » United Arab Emirates » and Rest of Middle East » and Africa
TABLE OF CONTENTS
| I. METHODOLOGY |
| II. EXECUTIVE SUMMARY |
| 1. MARKET OVERVIEW |
| Influencer Market Insights |
| World Market Trajectories |
| A Prelude to Osteoporosis |
| Growing Geriatric Population and Rising Incidence of Osteoporosis Drive the Global Osteoporosis Market |
| Developed Regions Dominate the Global Market, Developing to Witness Fastest Growth |
| Bisphosphonates - The Largest Category of Drugs for Treating Osteoporosis |
| Approved Drugs for Treatment of Osteoporosis |
| Select Recent Osteoporosis Drug Approvals |
| Osteoporosis Therapeutics – Global Key Competitors Percentage Market Share in 2022 (E) |
| Sales of Leading Osteoporosis Therapeutics: 2018 |
| Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2022 (E) |
| Impact of Covid-19 and a Looming Global Recession |
| 2. FOCUS ON SELECT PLAYERS |
| Amgen, Inc. (US) |
| Chugai Pharmaceutical Co., Ltd. (Japan) |
| Daiichi Sankyo Co., Ltd. (Japan) |
| Eisai Co., Ltd. (Japan) |
| Eli Lilly and Company (US) |
| F. Hoffmann-La Roche Ltd. (Switzerland) |
| Merck & Co. Inc. (USA) |
| Novartis International AG (Switzerland) |
| Pfizer, Inc. (US) |
| Radius Health, Inc. (USA) |
| 3. MARKET TRENDS & DRIVERS |
| Growing Incidence of Osteoporosis Augurs Well for Osteoporosis Therapeutics |
| TABLE: Global Osteoporosis Prevalence by Country/Region (2012 & 2022P): Number of People with Osteoporosis in Millions for US, EU, Japan, China and India |
| TABLE: % of Women Affected by Osteoporosis |
| Osteoporosis – Factsheet |
| Osteoporosis in Men |
| Rising Geriatric Population and the Associated Bone Health Issues to Drive Market Gains |
| Global Population of 65+ Individuals (In 000s) by Region for the Years 2015, 2020 & 2025 |
| Rising Prevalence of Osteoporosis in Post-menopausal Women Propels Market Growth |
| Changing Lifestyle Impacting Bone Health |
| Recommended Daily Intake of Calcium and Vitamin D |
| Increasing Awareness Related to Osteoporosis Care |
| New Product Launches Foster Market Growth |
| 4. GLOBAL MARKET PERSPECTIVE |
| World Recent Past, Current & Future Analysis for Osteoporosis Therapeutics by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2027 and % CAGR |
| World Historic Review for Osteoporosis Therapeutics by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR |
| World 15-Year Perspective for Osteoporosis Therapeutics by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets for Years 2012, 2021 & 2027 |
| World Recent Past, Current & Future Analysis for Bisphosphonates by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2027 and % CAGR |
| World Historic Review for Bisphosphonates by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR |
| World 15-Year Perspective for Bisphosphonates by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2012, 2021 & 2027 |
| World Recent Past, Current & Future Analysis for Parathyroid Hormone Therapy by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2027 and % CAGR |
| World Historic Review for Parathyroid Hormone Therapy by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR |
| World 15-Year Perspective for Parathyroid Hormone Therapy by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2012, 2021 & 2027 |
| World Recent Past, Current & Future Analysis for Calcitonin by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2027 and % CAGR |
| World Historic Review for Calcitonin by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR |
| World 15-Year Perspective for Calcitonin by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2012, 2021 & 2027 |
| World Recent Past, Current & Future Analysis for Selective Estrogen Inhibitors Modulator (SERM) by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2027 and % CAGR |
| World Historic Review for Selective Estrogen Inhibitors Modulator (SERM) by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR |
| World 15-Year Perspective for Selective Estrogen Inhibitors Modulator (SERM) by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2012, 2021 & 2027 |
| World Recent Past, Current & Future Analysis for Rank Ligand Inhibitors by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2027 and % CAGR |
| World Historic Review for Rank Ligand Inhibitors by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR |
| World 15-Year Perspective for Rank Ligand Inhibitors by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2012, 2021 & 2027 |
| World Recent Past, Current & Future Analysis for Oral by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2027 and % CAGR |
| World Historic Review for Oral by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR |
| World 15-Year Perspective for Oral by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2012, 2021 & 2027 |
| World Recent Past, Current & Future Analysis for Injectables by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2027 and % CAGR |
| World Historic Review for Injectables by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR |
| World 15-Year Perspective for Injectables by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2012, 2021 & 2027 |
| World Recent Past, Current & Future Analysis for Other Routes of Administration by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2027 and % CAGR |
| World Historic Review for Other Routes of Administration by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR |
| World 15-Year Perspective for Other Routes of Administration by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2012, 2021 & 2027 |
| III. MARKET ANALYSIS |
| UNITED STATES |
| Osteoporosis Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United States for 2022 (E) |
| USA Recent Past, Current & Future Analysis for Osteoporosis Therapeutics by Drug Class - Bisphosphonates, Parathyroid Hormone Therapy, Calcitonin, Selective Estrogen Inhibitors Modulator (SERM) and Rank Ligand Inhibitors - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR |
| USA Historic Review for Osteoporosis Therapeutics by Drug Class - Bisphosphonates, Parathyroid Hormone Therapy, Calcitonin, Selective Estrogen Inhibitors Modulator (SERM) and Rank Ligand Inhibitors Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR |
| USA 15-Year Perspective for Osteoporosis Therapeutics by Drug Class - Percentage Breakdown of Value Sales for Bisphosphonates, Parathyroid Hormone Therapy, Calcitonin, Selective Estrogen Inhibitors Modulator (SERM) and Rank Ligand Inhibitors for the Years 2012, 2021 & 2027 |
| USA Recent Past, Current & Future Analysis for Osteoporosis Therapeutics by Route Of Administration - Oral, Injectables and Other Routes of Administration - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR |
| USA Historic Review for Osteoporosis Therapeutics by Route Of Administration - Oral, Injectables and Other Routes of Administration Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR |
| USA 15-Year Perspective for Osteoporosis Therapeutics by Route Of Administration - Percentage Breakdown of Value Sales for Oral, Injectables and Other Routes of Administration for the Years 2012, 2021 & 2027 |
| CANADA |
| Canada Recent Past, Current & Future Analysis for Osteoporosis Therapeutics by Drug Class - Bisphosphonates, Parathyroid Hormone Therapy, Calcitonin, Selective Estrogen Inhibitors Modulator (SERM) and Rank Ligand Inhibitors - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR |
| Canada Historic Review for Osteoporosis Therapeutics by Drug Class - Bisphosphonates, Parathyroid Hormone Therapy, Calcitonin, Selective Estrogen Inhibitors Modulator (SERM) and Rank Ligand Inhibitors Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR |
| Canada 15-Year Perspective for Osteoporosis Therapeutics by Drug Class - Percentage Breakdown of Value Sales for Bisphosphonates, Parathyroid Hormone Therapy, Calcitonin, Selective Estrogen Inhibitors Modulator (SERM) and Rank Ligand Inhibitors for the Years 2012, 2021 & 2027 |
| Canada Recent Past, Current & Future Analysis for Osteoporosis Therapeutics by Route Of Administration - Oral, Injectables and Other Routes of Administration - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR |
| Canada Historic Review for Osteoporosis Therapeutics by Route Of Administration - Oral, Injectables and Other Routes of Administration Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR |
| Canada 15-Year Perspective for Osteoporosis Therapeutics by Route Of Administration - Percentage Breakdown of Value Sales for Oral, Injectables and Other Routes of Administration for the Years 2012, 2021 & 2027 |
| JAPAN |
| Osteoporosis Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Japan for 2022 (E) |
| Japan Recent Past, Current & Future Analysis for Osteoporosis Therapeutics by Drug Class - Bisphosphonates, Parathyroid Hormone Therapy, Calcitonin, Selective Estrogen Inhibitors Modulator (SERM) and Rank Ligand Inhibitors - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR |
| Japan Historic Review for Osteoporosis Therapeutics by Drug Class - Bisphosphonates, Parathyroid Hormone Therapy, Calcitonin, Selective Estrogen Inhibitors Modulator (SERM) and Rank Ligand Inhibitors Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR |
| Japan 15-Year Perspective for Osteoporosis Therapeutics by Drug Class - Percentage Breakdown of Value Sales for Bisphosphonates, Parathyroid Hormone Therapy, Calcitonin, Selective Estrogen Inhibitors Modulator (SERM) and Rank Ligand Inhibitors for the Years 2012, 2021 & 2027 |
| Japan Recent Past, Current & Future Analysis for Osteoporosis Therapeutics by Route Of Administration - Oral, Injectables and Other Routes of Administration - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR |
| Japan Historic Review for Osteoporosis Therapeutics by Route Of Administration - Oral, Injectables and Other Routes of Administration Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR |
| Japan 15-Year Perspective for Osteoporosis Therapeutics by Route Of Administration - Percentage Breakdown of Value Sales for Oral, Injectables and Other Routes of Administration for the Years 2012, 2021 & 2027 |
| CHINA |
| Osteoporosis Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in China for 2022 (E) |
| China Recent Past, Current & Future Analysis for Osteoporosis Therapeutics by Drug Class - Bisphosphonates, Parathyroid Hormone Therapy, Calcitonin, Selective Estrogen Inhibitors Modulator (SERM) and Rank Ligand Inhibitors - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR |
| China Historic Review for Osteoporosis Therapeutics by Drug Class - Bisphosphonates, Parathyroid Hormone Therapy, Calcitonin, Selective Estrogen Inhibitors Modulator (SERM) and Rank Ligand Inhibitors Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR |
| China 15-Year Perspective for Osteoporosis Therapeutics by Drug Class - Percentage Breakdown of Value Sales for Bisphosphonates, Parathyroid Hormone Therapy, Calcitonin, Selective Estrogen Inhibitors Modulator (SERM) and Rank Ligand Inhibitors for the Years 2012, 2021 & 2027 |
| China Recent Past, Current & Future Analysis for Osteoporosis Therapeutics by Route Of Administration - Oral, Injectables and Other Routes of Administration - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR |
| China Historic Review for Osteoporosis Therapeutics by Route Of Administration - Oral, Injectables and Other Routes of Administration Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR |
| China 15-Year Perspective for Osteoporosis Therapeutics by Route Of Administration - Percentage Breakdown of Value Sales for Oral, Injectables and Other Routes of Administration for the Years 2012, 2021 & 2027 |
| EUROPE |
| Osteoporosis Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Europe for 2022 (E) |
| Europe Recent Past, Current & Future Analysis for Osteoporosis Therapeutics by Geographic Region - France, Germany, Italy, UK and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2027 and % CAGR |
| Europe Historic Review for Osteoporosis Therapeutics by Geographic Region - France, Germany, Italy, UK and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR |
| Europe 15-Year Perspective for Osteoporosis Therapeutics by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK and Rest of Europe Markets for Years 2012, 2021 & 2027 |
| Europe Recent Past, Current & Future Analysis for Osteoporosis Therapeutics by Drug Class - Bisphosphonates, Parathyroid Hormone Therapy, Calcitonin, Selective Estrogen Inhibitors Modulator (SERM) and Rank Ligand Inhibitors - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR |
| Europe Historic Review for Osteoporosis Therapeutics by Drug Class - Bisphosphonates, Parathyroid Hormone Therapy, Calcitonin, Selective Estrogen Inhibitors Modulator (SERM) and Rank Ligand Inhibitors Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR |
| Europe 15-Year Perspective for Osteoporosis Therapeutics by Drug Class - Percentage Breakdown of Value Sales for Bisphosphonates, Parathyroid Hormone Therapy, Calcitonin, Selective Estrogen Inhibitors Modulator (SERM) and Rank Ligand Inhibitors for the Years 2012, 2021 & 2027 |
| Europe Recent Past, Current & Future Analysis for Osteoporosis Therapeutics by Route Of Administration - Oral, Injectables and Other Routes of Administration - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR |
| Europe Historic Review for Osteoporosis Therapeutics by Route Of Administration - Oral, Injectables and Other Routes of Administration Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR |
| Europe 15-Year Perspective for Osteoporosis Therapeutics by Route Of Administration - Percentage Breakdown of Value Sales for Oral, Injectables and Other Routes of Administration for the Years 2012, 2021 & 2027 |
| FRANCE |
| Osteoporosis Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in France for 2022 (E) |
| France Recent Past, Current & Future Analysis for Osteoporosis Therapeutics by Drug Class - Bisphosphonates, Parathyroid Hormone Therapy, Calcitonin, Selective Estrogen Inhibitors Modulator (SERM) and Rank Ligand Inhibitors - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR |
| France Historic Review for Osteoporosis Therapeutics by Drug Class - Bisphosphonates, Parathyroid Hormone Therapy, Calcitonin, Selective Estrogen Inhibitors Modulator (SERM) and Rank Ligand Inhibitors Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR |
| France 15-Year Perspective for Osteoporosis Therapeutics by Drug Class - Percentage Breakdown of Value Sales for Bisphosphonates, Parathyroid Hormone Therapy, Calcitonin, Selective Estrogen Inhibitors Modulator (SERM) and Rank Ligand Inhibitors for the Years 2012, 2021 & 2027 |
| France Recent Past, Current & Future Analysis for Osteoporosis Therapeutics by Route Of Administration - Oral, Injectables and Other Routes of Administration - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR |
| France Historic Review for Osteoporosis Therapeutics by Route Of Administration - Oral, Injectables and Other Routes of Administration Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR |
| France 15-Year Perspective for Osteoporosis Therapeutics by Route Of Administration - Percentage Breakdown of Value Sales for Oral, Injectables and Other Routes of Administration for the Years 2012, 2021 & 2027 |
| GERMANY |
| Osteoporosis Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Germany for 2022 (E) |
| Germany Recent Past, Current & Future Analysis for Osteoporosis Therapeutics by Drug Class - Bisphosphonates, Parathyroid Hormone Therapy, Calcitonin, Selective Estrogen Inhibitors Modulator (SERM) and Rank Ligand Inhibitors - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR |
| Germany Historic Review for Osteoporosis Therapeutics by Drug Class - Bisphosphonates, Parathyroid Hormone Therapy, Calcitonin, Selective Estrogen Inhibitors Modulator (SERM) and Rank Ligand Inhibitors Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR |
| Germany 15-Year Perspective for Osteoporosis Therapeutics by Drug Class - Percentage Breakdown of Value Sales for Bisphosphonates, Parathyroid Hormone Therapy, Calcitonin, Selective Estrogen Inhibitors Modulator (SERM) and Rank Ligand Inhibitors for the Years 2012, 2021 & 2027 |
| Germany Recent Past, Current & Future Analysis for Osteoporosis Therapeutics by Route Of Administration - Oral, Injectables and Other Routes of Administration - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR |
| Germany Historic Review for Osteoporosis Therapeutics by Route Of Administration - Oral, Injectables and Other Routes of Administration Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR |
| Germany 15-Year Perspective for Osteoporosis Therapeutics by Route Of Administration - Percentage Breakdown of Value Sales for Oral, Injectables and Other Routes of Administration for the Years 2012, 2021 & 2027 |
| ITALY |
| Italy Recent Past, Current & Future Analysis for Osteoporosis Therapeutics by Drug Class - Bisphosphonates, Parathyroid Hormone Therapy, Calcitonin, Selective Estrogen Inhibitors Modulator (SERM) and Rank Ligand Inhibitors - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR |
| Italy Historic Review for Osteoporosis Therapeutics by Drug Class - Bisphosphonates, Parathyroid Hormone Therapy, Calcitonin, Selective Estrogen Inhibitors Modulator (SERM) and Rank Ligand Inhibitors Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR |
| Italy 15-Year Perspective for Osteoporosis Therapeutics by Drug Class - Percentage Breakdown of Value Sales for Bisphosphonates, Parathyroid Hormone Therapy, Calcitonin, Selective Estrogen Inhibitors Modulator (SERM) and Rank Ligand Inhibitors for the Years 2012, 2021 & 2027 |
| Italy Recent Past, Current & Future Analysis for Osteoporosis Therapeutics by Route Of Administration - Oral, Injectables and Other Routes of Administration - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR |
| Italy Historic Review for Osteoporosis Therapeutics by Route Of Administration - Oral, Injectables and Other Routes of Administration Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR |
| Italy 15-Year Perspective for Osteoporosis Therapeutics by Route Of Administration - Percentage Breakdown of Value Sales for Oral, Injectables and Other Routes of Administration for the Years 2012, 2021 & 2027 |
| UNITED KINGDOM |
| Osteoporosis Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United Kingdom for 2022 (E) |
| UK Recent Past, Current & Future Analysis for Osteoporosis Therapeutics by Drug Class - Bisphosphonates, Parathyroid Hormone Therapy, Calcitonin, Selective Estrogen Inhibitors Modulator (SERM) and Rank Ligand Inhibitors - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR |
| UK Historic Review for Osteoporosis Therapeutics by Drug Class - Bisphosphonates, Parathyroid Hormone Therapy, Calcitonin, Selective Estrogen Inhibitors Modulator (SERM) and Rank Ligand Inhibitors Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR |
| UK 15-Year Perspective for Osteoporosis Therapeutics by Drug Class - Percentage Breakdown of Value Sales for Bisphosphonates, Parathyroid Hormone Therapy, Calcitonin, Selective Estrogen Inhibitors Modulator (SERM) and Rank Ligand Inhibitors for the Years 2012, 2021 & 2027 |
| UK Recent Past, Current & Future Analysis for Osteoporosis Therapeutics by Route Of Administration - Oral, Injectables and Other Routes of Administration - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR |
| UK Historic Review for Osteoporosis Therapeutics by Route Of Administration - Oral, Injectables and Other Routes of Administration Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR |
| UK 15-Year Perspective for Osteoporosis Therapeutics by Route Of Administration - Percentage Breakdown of Value Sales for Oral, Injectables and Other Routes of Administration for the Years 2012, 2021 & 2027 |
| REST OF EUROPE |
| Rest of Europe Recent Past, Current & Future Analysis for Osteoporosis Therapeutics by Drug Class - Bisphosphonates, Parathyroid Hormone Therapy, Calcitonin, Selective Estrogen Inhibitors Modulator (SERM) and Rank Ligand Inhibitors - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR |
| Rest of Europe Historic Review for Osteoporosis Therapeutics by Drug Class - Bisphosphonates, Parathyroid Hormone Therapy, Calcitonin, Selective Estrogen Inhibitors Modulator (SERM) and Rank Ligand Inhibitors Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR |
| Rest of Europe 15-Year Perspective for Osteoporosis Therapeutics by Drug Class - Percentage Breakdown of Value Sales for Bisphosphonates, Parathyroid Hormone Therapy, Calcitonin, Selective Estrogen Inhibitors Modulator (SERM) and Rank Ligand Inhibitors for the Years 2012, 2021 & 2027 |
| Rest of Europe Recent Past, Current & Future Analysis for Osteoporosis Therapeutics by Route Of Administration - Oral, Injectables and Other Routes of Administration - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR |
| Rest of Europe Historic Review for Osteoporosis Therapeutics by Route Of Administration - Oral, Injectables and Other Routes of Administration Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR |
| Rest of Europe 15-Year Perspective for Osteoporosis Therapeutics by Route Of Administration - Percentage Breakdown of Value Sales for Oral, Injectables and Other Routes of Administration for the Years 2012, 2021 & 2027 |
| ASIA-PACIFIC |
| Osteoporosis Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Asia-Pacific for 2022 (E) |
| Asia-Pacific Recent Past, Current & Future Analysis for Osteoporosis Therapeutics by Drug Class - Bisphosphonates, Parathyroid Hormone Therapy, Calcitonin, Selective Estrogen Inhibitors Modulator (SERM) and Rank Ligand Inhibitors - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR |
| Asia-Pacific Historic Review for Osteoporosis Therapeutics by Drug Class - Bisphosphonates, Parathyroid Hormone Therapy, Calcitonin, Selective Estrogen Inhibitors Modulator (SERM) and Rank Ligand Inhibitors Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR |
| Asia-Pacific 15-Year Perspective for Osteoporosis Therapeutics by Drug Class - Percentage Breakdown of Value Sales for Bisphosphonates, Parathyroid Hormone Therapy, Calcitonin, Selective Estrogen Inhibitors Modulator (SERM) and Rank Ligand Inhibitors for the Years 2012, 2021 & 2027 |
| Asia-Pacific Recent Past, Current & Future Analysis for Osteoporosis Therapeutics by Route Of Administration - Oral, Injectables and Other Routes of Administration - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR |
| Asia-Pacific Historic Review for Osteoporosis Therapeutics by Route Of Administration - Oral, Injectables and Other Routes of Administration Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR |
| Asia-Pacific 15-Year Perspective for Osteoporosis Therapeutics by Route Of Administration - Percentage Breakdown of Value Sales for Oral, Injectables and Other Routes of Administration for the Years 2012, 2021 & 2027 |
| REST OF WORLD |
| Rest of World Recent Past, Current & Future Analysis for Osteoporosis Therapeutics by Drug Class - Bisphosphonates, Parathyroid Hormone Therapy, Calcitonin, Selective Estrogen Inhibitors Modulator (SERM) and Rank Ligand Inhibitors - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR |
| Rest of World Historic Review for Osteoporosis Therapeutics by Drug Class - Bisphosphonates, Parathyroid Hormone Therapy, Calcitonin, Selective Estrogen Inhibitors Modulator (SERM) and Rank Ligand Inhibitors Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR |
| Rest of World 15-Year Perspective for Osteoporosis Therapeutics by Drug Class - Percentage Breakdown of Value Sales for Bisphosphonates, Parathyroid Hormone Therapy, Calcitonin, Selective Estrogen Inhibitors Modulator (SERM) and Rank Ligand Inhibitors for the Years 2012, 2021 & 2027 |
| Rest of World Recent Past, Current & Future Analysis for Osteoporosis Therapeutics by Route Of Administration - Oral, Injectables and Other Routes of Administration - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR |
| Rest of World Historic Review for Osteoporosis Therapeutics by Route Of Administration - Oral, Injectables and Other Routes of Administration Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR |
| Rest of World 15-Year Perspective for Osteoporosis Therapeutics by Route Of Administration - Percentage Breakdown of Value Sales for Oral, Injectables and Other Routes of Administration for the Years 2012, 2021 & 2027 |
| IV. COMPETITION |
| Total Companies Profiled: 53 (including Divisions/Subsidiaries - 53) |
PREVIEW REPORT
Our robust permission-based engagement strategy requires a one-time double opt-in and/or re-consent for all users. We will re-establish consent once a year from date of last use. Both these practices exceed GDPR mandates.
What we store: Primary coordinates such as email, company address and phone. In-house developed influencer rank.
How we store: Encrypted and additionally secured by firewalls.
How we use your data: Only to contact you directly. We never share your coordinates with any individual or entity outside our company for any reason.
Privacy queries: Privacy@StrategyR.com